top of page
Open Site Navigation

View Video: Our Director of Patient Advocacy moderated an insightful panel discussion at the White House Cancer Moonshot Brain Cancers Forum on GBM & DIPG on May 25, 2023

May 25, 2023

SonALAsense Welcomes Dr. Ely Benaim as Chief Medical Officer and Executive Vice President of Development

May 9, 2023

Highly accomplished Pediatric Oncologist from St. Jude Children’s Research Hospital and CMO for Novocure Brings Great Promise for People with Challenging Conditions

SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma

March 8, 2023

Company’s Phase 2 clinical trial aims to find meaningful clinical endpoints regarding tumor regression and survival rates.

Fast Company’s ‘World Changing Ideas Awards’ Honorably Mentions SonALAsense

January 11, 2023

Fast Company has listed SonALAsense as an honorable mention in the health category of their annual ‘World Changing Ideas Awards’.

SonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain Cancer

September 13, 2022

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

April Freeman Brings Her Personal and Professional Experience to SonALAsense as Patient Advocate

July 28, 2022

April recently joined SonALAsense as Director of Patient Advocacy and Engagement, helping build alliances with patient and trade organizations / associations to raise awareness of, and educate on, sonodynamic therapy and recruit patients for recurrent glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) clinical trials.

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer

June 28, 2022

Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.

SonALAsense Q&A with Dr. Scott Plotkin

June 21, 2022

Dr. Scott Plotkin, MD, PhD is the Executive Director at the Pappas Center for Neuro-Oncology at Massachusetts General Hospital and the Giovanni Armenise– Harvard Professor of Neurology at Harvard Medical School. He completed his neurology training at Mass General Brigham and Women's Hospital in Boston in 2002, and then trained in neuro-oncology at Mass General Hospital the following year. He has been on the faculty ever since and now also sits on the Scientific Advisory Board for SonALAsense.

Dr. Stuart Marcus Creates SonALAsense To Treat Deadly Cancers

February 3, 2022

Dr. Stuart Marcus has devoted most of his life to eradicating cancer after experiencing the horrors of the disease taking his beloved grandmother as a child in the ‘50s when few good options for treatment were available.

Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma

September 20, 2021

Trial provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors and other lethal cancers

The Ins and Outs of Glioblastoma From Standard of Care to Breakthrough Treatments for Brain Tumor Patients

August 12, 2021

Professor Mitchel S. Berger, MD, Director of the UCSF Brain Tumor Center

Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer

March 30, 2021

Study combines metabolic targeting of glioblastoma with inert drug activated using MR-guided focused ultrasound


bottom of page